Targeted Sequencing for Brain Tumors

Next-generation sequencing has revolutionized genomic studies of brain tumors and facilitated the development of precise brain tumor therapy based on molecular tumor characterization. Targeted sequencing covers fewer regions and allows effective cost control, especially for low-frequency somatic mutation detection. With high-depth sequencing, it is possible to detect low-frequency mutations.

Targeted sequencing services we offer for brain tumors

Targeted sequencing focuses only on genes of interest. Alfa Cytology can accurately detect mutations in brain tumor samples with targeted sequencing technology. Whether you focus on a few genes or hundreds of genes, we offer targeted sequencing with greater sensitivity and specificity, higher coverage, and high-quality data. It helps you to research key genes and important variants associated with tumor development and individualized drug use.

Tumor mutational load (TMB) analysis service

Tumor cells usually have various somatic mutations that are associated with tumorigenesis and progression. TMB indicates the number of somatic mutations per million bases in the genome of a tumor cell. We can analyze brain tumor TMB based on high-throughput targeted sequencing data.

• Sequences of selected exons and upstream and downstream regions of target genes in brain tumor samples and paired control samples are sequenced by high-throughput targeted sequencing.
• Sequence data obtained from brain tumor samples and paired control samples are compared to human reference genome sequences.
• Calculating the number of somatic mutations in the sequences of selected exons and upstream and downstream regions of the said target gene in the brain tumor sample.
• Summing the number of mutations in the selected exons and upstream and downstream regions of the target gene to obtain the total number of mutations.
• The total region length is obtained by adding the lengths of the selected exons and the upstream and downstream regions of the target gene.
• The final TMB is calculated by the formula.

Brain tumor-targeted sequencing data parsing service

We can perform generic analysis of different amplicon libraries customized by different customers and obtain mutation analysis results that are significantly correlated with brain tumor binding. This adds a comprehensive assessment of the amplification efficiency of targeted libraries and primer sequence trimming steps to improve the reliability of the analysis results.

• Acquisition of reading sequences containing mutational information.
• Sequencing quality control.
• Quality control of the amplification efficiency of the target amplification region corresponding to the amplicon.
• Deletion of primer sequences from the read sequences.
• The read segment sequence is compared to the reference sequence of the target region to obtain the reading segment on the comparison and the comparison.
• Identify mutations in the read segment sequences compared to the target region.
• Perform sample screening based on the sequencing depth of the mutation site.
• Combine the recorded mutations to screen for significantly different mutations.
• Combine information for association analysis.

Wide range of applications

• Discovery of genetic biomarkers associated with brain tumors.
• Characterization of genetic correlations as a specific phenotype, such as drug response.
• Genotyping and classification of eukaryotic and/or prokaryotic cell lines.
• Design of genetic assays, such as pharmacogenomic assays and brain oncology assays.

Alfa Cytology offers targeted sequencing services to efficiently analyze customer-selected genes through high-throughput sequencing technologies that can help you identify point mutations, insertions or deletions, copy number changes, and gene rearrangements in the brain tumor genome. Please contact our staff for the latest solutions.